Regeneron Pharmaceuticals (REGN) Expected to Announce Quarterly Earnings on Friday

Regeneron Pharmaceuticals (NASDAQ:REGN) is projected to release its earnings data before the market opens on Friday, February 7th. Analysts expect Regeneron Pharmaceuticals to post earnings of $11.21 per share and revenue of $3.76 billion for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $683.08 on Friday. Regeneron Pharmaceuticals has a one year low of $666.25 and a one year high of $1,211.20. The company has a market cap of $75.06 billion, a PE ratio of 16.90, a P/E/G ratio of 1.59 and a beta of 0.10. The stock has a 50-day moving average of $723.36 and a 200-day moving average of $928.61. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Analysts Set New Price Targets

Several research firms have recently commented on REGN. Barclays decreased their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Piper Sandler lowered their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price for the company. Bank of America reaffirmed an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,004.57.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.